Answers are grounded in this paper and cite their sources.
This article describes the identification and management of depression due to bipolar disease. Data on the benefits and risks of the two therapies approved by the FDA, as well as those of nonapproved therapies, are reviewed.
No takes yet. Share an insight, caveat, or question.
Mark A. Frye (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: